FundedIQ
Biotechnology

Salus BioMed

Salus BioMed is an innovative biomedical company that specializes in developing genetic sequencing technology and spatial omics products.

salus-bio.com Shenzhen, China 51-100 employees
Total raised
$7.0M
Rounds
1
Latest
Series B
Oct 2025

Salus BioMed is an innovative biomedical company that specializes in developing genetic sequencing technology and spatial omics products.

Salus BioMed has raised $7.0M across 1 round. Its most recent round was a Series B of $7.0M in Oct 2025. Full funding history, investors, and team are detailed below.

Funding history

1 round · 1 visible Unlock with plan

1 round on record.

Date
Round
Amount
Lead investor
Oct 12, 2025
Series B
$7.0M

Unlock the lead investor and full details for this round.

Unlock funding history →

People

Unlock with plan

Founders, executives, and decision-makers — sourced and refreshed weekly.

Name
Role
LinkedIn

See who runs this company — founders and key execs, with titles and LinkedIn profiles, ready to export.

Unlock people data →

Salus BioMed is featured in

Similar companies

Enze Kangtai

Echo Biotech is a biotech firm mainly engaged in the R&D and production of exosome molecular diagnostic products and exosome research.

Series B $14.0M
Epigenic Therapeutics

Epigenic Therapeutics is a drug development company that develops gene modulation therapies through the regulation of epigenetic mechanisms.

Series B $60.0M
CANbridge Pharmaceuticals

CANbridge Pharmaceuticals is a bio-pharmaceutical company accelerating development and commercialization of specialty healthcare products for serious and critical medical conditions in China and North Asia (Korea and Taiwan). CANbridge develops partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. CANbridge also licenses or obtains exclusive rights to commercialize drug and device products that are approved in their home markets for commercialization in China and North Asia.

$43.0M
Harbour Biomed

Harbour BioMed is a developer of bio-therapeutics aimed at immuno-oncology and inflammatory diseases. The company engages in discovery and development programs that are centered around two patented transgenic mouse platforms for generating both fully human monoclonal antibodies (H2L2) and heavy chain only antibodies (HCAb) based immune cell engager (HBICETM) bispecific antibodies, thereby enabling medical professionals to generate potential therapeutic antibodies and accelerate drug discovery and development.

$103M
JW Therapeutics

JW Therapeutics is a developer of cell-based therapy technologies created to revolutionize cancer treatment.The company focuses on development, transformation and promotion of cell-based immunotherapies that uses chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to regulate the body's immune system, enabling doctors to save the lives of cancer patients and improve the quality of life.

$100M
immunitoAI

ImmunitoAI is a life sciences (biotech) platform that leverages AI to revolutionize antibody discovery & therapeutics.

Series A $6.1M
AI Metrics

AI Metrics is an early stage company creating transformational image analysis technology that positions radiologists to be the most efficient, valuable clinicians in the patient care continuum

Venture - Series Unknown $950k
Luminate Medical

Luminate Medical develops a medical device designed to prevent hair loss during chemotherapy. Luminate Medical recognises that hair is an essential element of personality and self-esteem, and is dedicated to using the latest advances in medical technology to protect this.

Venture - Series Unknown $17.0M
Hermes Biosciences

Hermes Biosciences describes a benchtop, hands-off extracellular vesicle isolation system designed to purify exosomes quickly, efficiently.

Seed $6.0M
InvenireX

InvenireX is a biotech company that provides molecular diagnostics services.

Seed $2.6M
Chromologics

Chromologics is a company that creates new and original food colorings utilizing natural ingredients. Derived from the Technical University of Denmark, this Danish biotech spin-out has established a biotech framework that employs fungi to generate exceptional and eco-friendly colorants.

Venture - Series Unknown $8.1M
Artios Pharma

Artios is an independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Established in May 2016, the Company is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. Artios is building a pipeline of next-generation DDR programs, including through a unique partnership with Cancer Research Technology (CRT), the development and commercialization arm of Cancer Research UK (CRUK), and with leading DNA repair researchers worldwide. The Company’s investors include SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund (managed by Sixth Element Capital), and AbbVie Ventures. Artios is based at the Babraham Institute in Cambridge, UK.

Series D $115M
Free · Every Monday

Know which startups just got funded. Every week.

Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.

Free. Sent every Monday. Unsubscribe anytime.